-
Drug-Device Combination Products: Making a Step Towards Better Adherence
Suzanne Elvidge
August 01, 2025
More than half of the world’s population takes at least one medication daily, but the safety and efficacy data from clinical trials isn’t always fully reflected in real world use.
-
Direct-to-Consumer and Direct-to-Patient Healthcare Models
Suzanne Elvidge
July 24, 2025
Accessing healthcare can be complex, and this complexity is driven by a number of different factors.
-
Meeting global quality standards: A look at CNS & cardiovascular APIs
Suzanne Elvidge
August 22, 2025
Active pharmaceutical ingredients (APIs) are the active ingredients used in pharmaceutical manufacturing and are formulated with excipients to create the finished drug form.
-
Radioconjugate Therapy: The Approval Process And the Market Landscap
Suzanne Elvidge
August 22, 2025
Radioconjugates combine targeted ligands with radioisotopes, enabling precision cancer therapy and theranostics. The $7.5B market by 2033 demands strict FDA safety/CMC data for NDA/BLA approval.
-
Beyond Antibiotics: The Expanding Role of Anti-Infective APIs in Bacterial Infection
Suzanne Elvidge
June 13, 2025
Beyond antibiotics, novel anti-infective approaches include AMPs targeting biofilms, FMT capsules ,nanoparticle delivery systems, and synbiotics to combat the global AMR crisis.
-
Radioconjugates: Targeting for Precision
Suzanne Elvidge
May 06, 2025
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
-
Now and Next in Type 2 Diabetes
Suzanne Elvidge
May 06, 2025
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
-
Oncolytic viruses in cancer treatment
Suzanne Elvidge
April 21, 2025
Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
-
Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes
Suzanne Elvidge
April 01, 2025
Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
-
Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards
Suzanne Elvidge
March 31, 2025
In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.